Niall Tebbutt

Is there a role for combined anti-PD-1/CTLA-4 checkpoint blockade in the management of advanced biliary tract cancers?

Oliver Klein, Damien Kee, Adnan Nagrial, Ben Markman, Craig Underhill, Michael Michael, Andreas Behren, Jodie Palmer, Niall C Tebbutt, Matteo S Carlino, Jonathan Cebon

Journal article  |  2023  |  Cancer

A Phase Ib/II Trial of Combined BRAF and EGFR Inhibition in BRAF V600E Positive Metastatic Colorectal Cancer and Other Cancers: The EVICT (Erlotinib and Vemurafenib In Combination Trial) Study.

Lavinia Tan, Ben Tran, Jeanne Tie, Ben Markman, Sumi Ananda, Niall C Tebbutt, Michael Michael, Emma Link, Stephen Q Wong, Sushma Chandrashekar, Jerick Guinto, David Ritchie, Rachel Koldej, Benjamin J Solomon, Grant A McArthur, Rodney J Hicks, Peter Gibbs, Sarah-Jane Dawson, Jayesh Desai

Journal article  |  2023  |  Clin Cancer Res

PURPOSE: BRAF V600E mutant metastatic colorectal cancer represents a significant clinical problem, with combination approaches bei..

Napabucasin Plus FOLFIRI in Patients With Previously Treated Metastatic Colorectal Cancer: Results From the Open-Label, Randomized Phase III CanStem303C Study.

Manish A Shah, Takayuki Yoshino, Niall C Tebbutt, Axel Grothey, Josep Tabernero, Rui-Hua Xu, Andres Cervantes, Sang Cheul Oh, Kensei Yamaguchi, Marwan Fakih, Alfredo Falcone, Christina Wu, Vi K Chiu, Jiri Tomasek, Johanna Bendell, Marilyn Fontaine, Matthew Hitron, Bo Xu, Julien Taieb, Eric Van Cutsem

Journal article  |  2023  |  Clin Colorectal Cancer

PURPOSE: Napabucasin is an investigational, orally administered reactive oxygen species generator bioactivated by intracellular an..

In colon cancer cells fascin1 regulates adherens junction remodeling.

Amin Esmaeilniakooshkghazi, Eric Pham, Sudeep P George, Afzal Ahrorov, Fabian R Villagomez, Michael Byington, Srijita Mukhopadhyay, Srinivas Patnaik, Jacinta C Conrad, Monali Naik, Saathvika Ravi, Niall Tebbutt, Jennifer Mooi, Camilla M Reehorst, John M Mariadason, Seema Khurana

Journal article  |  2023  |  FASEB J

Adherens junctions (AJs) are a defining feature of all epithelial cells. They regulate epithelial tissue architecture and integrit..

Stereotactic radiotherapy produces a durable response in a peri-rectal GIST

Dr Nathanial Harris, Dr Olivia Fraser, Melanie Bauer, Farshad Foroudi, Dr Andrew Bui, Niall Tebbutt, Michael Chao, Daryl Lim Joon

Journal article  |  2023  |  Advances in Radiation Oncology

INTEGRATE II: randomised phase III controlled trials of regorafenib containing regimens versus standard of care in refractory Advanced Gastro-Oesophageal Cancer (AGOC): a study by the Australasian Gastro-Intestinal Trials Group (AGITG).

Lyn Ley Lam, Nick Pavlakis, Kohei Shitara, Katrin M Sjoquist, Andrew J Martin, Sonia Yip, Yoon-Koo Kang, Yung-Jue Bang, Li-Tzong Chen, Markus Moehler, Tanios Bekaii-Saab, Thierry Alcindor, Christopher J O'Callaghan, Niall C Tebbutt, Wendy Hague, Howard Chan, Sun Young Rha, Keun-Wook Lee, Val Gebski, Anthony Jaworski, et al.

Journal article  |  2023  |  BMC Cancer

BACKGROUND: Advanced gastro-oesophageal cancer (AGOC) carries a poor prognosis. No standard of care treatment options are availabl..

Author Correction: DUSP5 is methylated in CIMP-high colorectal cancer but is not a major regulator of intestinal cell proliferation and tumorigenesis.

Lars Tögel, Rebecca Nightingale, Rui Wu, Anderly C Chüeh, Sheren Al-Obaidi, Ian Luk, Mercedes Dávalos-Salas, Fiona Chionh, Carmel Murone, Daniel D Buchanan, Zac Chatterton, Oliver M Sieber, Diego Arango, Niall C Tebbutt, David Williams, Amardeep S Dhillon, John M Mariadason

Journal article  |  2023  |  Sci Rep

The Article contains an error in Figure 2, where the western blot showing tubulin has 7 lanes instead of 6 lanes. The correct Figu..

SCORE: A multisite randomised controlled trial evaluating shared care for colorectal cancer survivors.

Michael Jefford, Jon D Emery, Andrew James Martin, Richard De Abreu Lourenco, Karolina Lisy, Mustafa Abdi Mohamed, Dorothy King, Niall C Tebbutt, Margaret Lee, Ashkan Mehrnejad, Adele Burgess, Julie Marker, Renee Eggins, Joseph Carrello, Penelope Schofield

Journal article  |  2023  |  Journal of Clinical Oncology

84 Background: Colorectal cancer (CRC) survivorship is rising. Few studies have considered shared follow up (FU) care (SC) betwee..

Bevacizumab in first-line therapy in lung metastases of colorectal cancer: An ARCAD pooled analysis.

Einat S Shmueli, Morteza Raeisi, Benoist Chibaudel, Herbert Hurwitz, Leonard B Saltz, Fairooz F Kabbinavar, Niall C Tebbutt, Axel Grothey, Richard Adams, John Raymond Zalcberg, Takayuki Yoshino, Jean-Baptiste Bachet, Romain Cohen, Lama Sharara, Thierry Andre, Qian Shi, Aimery De Gramont

Journal article  |  2023  |  Journal of Clinical Oncology

118 Background: Anti-VEGF is widely used in the treatment (trt) of metastatic colorectal cancer (mCRC). Only studies with bevaciz..

Genotype-Tailored ERK/MAPK Pathway and HDAC Inhibition Rewires the Apoptotic Rheostat to Trigger Colorectal Cancer Cell Death.

Laura J Jenkins, Ian Y Luk, W Douglas Fairlie, Erinna F Lee, Michelle Palmieri, Kael L Schoffer, Tao Tan, Irvin Ng, Natalia Vukelic, Sharon Tran, Janson WT Tse, Rebecca Nightingale, Zakia Alam, Fiona Chionh, George Iatropoulos, Matthias Ernst, Shoukat Afshar-Sterle, Jayesh Desai, Peter Gibbs, Oliver M Sieber, et al.

Journal article  |  2023  |  Mol Cancer Ther

The EGFR/RAS/MEK/ERK signaling pathway (ERK/MAPK) is hyperactivated in most colorectal cancers. A current limitation of inhibitors..